The stock will trade on upcoming pipeline catalysts (ATI-052 Phase 1b POC data, bosakitug Phase 2 AD data, both expected H2 2026) rather than quarterly financials. Monitor for data readouts and any partnership/BD announcements that could extend the cash runway beyond 2028.
Price Chart
Executive Summary
Aclaris Therapeutics reported Q2 2026 net loss of $21.5M ($-0.15/share) on revenue of $1.6M, slightly better than consensus EPS of $-0.16 but with revenue declining 8.3% YoY from $1.8M. The clinical-stage biopharma reaffirmed upcoming catalysts including Phase 1b POC data for ATI-052 and Phase 2 bosakitug results in H2 2026, and raised $40.2M in an ATM offering post-quarter to extend cash runway through 2028. The filing is neutral: the EPS beat is modest and typical for a pre-revenue biotech, while the revenue decline and widening loss are offset by a strong pipeline catalyst calendar and extended cash runway.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $21.5M vs $15.4M in Q2 2025; net loss per share of $-0.15 vs $-0.13
- Total revenue of $1.6M declined 8.3% YoY from $1.8M
- Cash, cash equivalents and marketable securities of $170.6M as of June 30, 2026
- Subsequent to quarter end, sold 7.3M shares for $40.2M in gross proceeds via ATM offering
- Reaffirmed timelines for Phase 1b POC trials of ATI-052 (asthma, AD) and Phase 2 bosakitug (AD) readouts in H2 2026
- Phase 2b program for ATI-052 and Phase 2b trial for modzatinib (ATI-2138) in lichen planus planned for Q4 2026
- IND filing for ATI-9494 on track for Q4 2026
- Cash runway expected to fund operations through end of 2028
Financial Impact
Q2 2026 net loss of $21.5M on revenue of $1.6M; cash burn of $38.0M in operating activities for H1 2026; $40.2M raised post-quarter via ATM
Risk Factors
- Clinical trial failure or disappointing data from ATI-052 or bosakitug trials
- Dilution from continued ATM sales or future equity offerings
- Widening operating losses as R&D spend increases for Phase 2b programs
- No approved products or recurring revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091629 |
| Document: acrs-20260806x8k.htm | 0001104659-26-091629 |
| Document: 0001104659-26-091629-index-headers.html | 0001104659-26-091629 |
| Document: 0001104659-26-091629-index.html | 0001104659-26-091629 |
| Document: 0001104659-26-091629.txt | 0001104659-26-091629 |
| 8-K Data (Synthetic) | 0001104659-26-091629 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $3.78 | awaiting T+5 | — | $3.63 (−3.97%) |
Oct 27, 2026 today | Press Release | $3.89 | awaiting T+5 | — | $3.63 (−6.68%) |
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.63 (−37.84%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.63 (−40.39%) |
Apr 28, 2026 26w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.63 (−13.98%) |
Apr 28, 2026 26w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.63 (−13.98%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.63 (−20.22%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.63 (+3.13%) |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | $3.63 (−1.63%) |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | $3.63 (−0.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers